Director/PDMR Shareholding

RNS Number : 7623F

ConvaTec Group PLC

23 March 2022

 

23 March 2022

ConvaTec Group Plc
("ConvaTec" or "the Company")
Director/PDMR Shareholding

The Company has been notified of the following transaction by a Person Discharging Managerial Responsibility ("PDMR") in ordinary shares of 10 pence each in the share capital of the Company ("Shares").

On 22 March 2022, Kim Lody, Non-Executive Director and PDMR, purchased 10,000 Shares at £2.04 per Share. Kim Lody's resulting shareholding is 10,000 Shares.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Kim Lody
2	Reason for the notification
a)	Position/Status	Non-Executive Director
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ConvaTec Group Plc
b)	LEI	213800LS272L4FIDOH92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 10p each in ConvaTec Group Plc ("Shares") GB00BD3VFW73
b)	Nature of the transaction	Purchase of shares on 22 March 2022
c)	Price(s) and volume(s)	Price(s) £2.04	Volume(s) 10,000
d)	Aggregated information - Aggregated volume  - Price	10,000 £20,400
e)	Date of the transaction	2022-03-22
f)	Place of the transaction	London Stock Exchange, Main Market (XLON)

Enquiries

Analysts and Investors

Kate Postans, VP Investor Relations, ConvaTec   [phone]

[e-mail]

Media

Buchanan: Charles Ryland / Chris Lane         [phone]         

ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92

About ConvaTec

ConvaTec is a global medical products and technologies company focused on solutions for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit  www.convatecgroup.com

 

END

 

 

DSHFLFFLVFIVFIF